Page last updated: 2024-10-31
entinostat and Weight Loss
entinostat has been researched along with Weight Loss in 1 studies
Weight Loss: Decrease in existing BODY WEIGHT.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|
| "The antiangiogenic tyrosine kinase inhibitor regorafenib provides a survival benefit in patients with previously treated metastatic colorectal cancer (CRC)." | 9.51 | Phase I Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer. ( Amaravadi, RK; Brown, TJ; DiCicco, L; Garcia-Marcano, L; Karasic, TB; Massa, RC; Mitchell, TC; O'Dwyer, PJ; O'Hara, MH; Reiss, KA; Schneider, C; Teitelbaum, UR, 2022) |
| "The antiangiogenic tyrosine kinase inhibitor regorafenib provides a survival benefit in patients with previously treated metastatic colorectal cancer (CRC)." | 5.51 | Phase I Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer. ( Amaravadi, RK; Brown, TJ; DiCicco, L; Garcia-Marcano, L; Karasic, TB; Massa, RC; Mitchell, TC; O'Dwyer, PJ; O'Hara, MH; Reiss, KA; Schneider, C; Teitelbaum, UR, 2022) |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
Authors
| Authors | Studies |
|---|
| Karasic, TB | 1 |
| Brown, TJ | 1 |
| Schneider, C | 1 |
| Teitelbaum, UR | 1 |
| Reiss, KA | 1 |
| Mitchell, TC | 1 |
| Massa, RC | 1 |
| O'Hara, MH | 1 |
| DiCicco, L | 1 |
| Garcia-Marcano, L | 1 |
| Amaravadi, RK | 1 |
| O'Dwyer, PJ | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status |
|---|
| Phase I/II Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer[NCT03215264] | Phase 1 | 20 participants (Actual) | Interventional | 2017-10-02 | Completed |
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Maximum Tolerated Dose (MTD) of Hydroxychloroquine and Entinostat in Combination With Regorafenib
Participants were evaluable for toxicity if they have taken one dose of HCQ and one dose of entinostat. To be considered for evaluability in a Phase I cohort in the absence of dose-limiting toxicity, patients should have completed > 85% of HCQ doses, and at least 3 of 4 entinostat doses. The MTD will be defined as a) the dose producing DLT in 1 out of 6 patients, or b) the dose level below the dose which produced DLT in ≥ 2 out of 3 patients, or in ≥ 2 out of 6 patients. DLTs will be defined by toxicity occurring during the first 4 weeks of this study. (NCT03215264)
Timeframe: 18 months
| Intervention | mg (Number) |
|---|
| Hydroxychloroquine Daily | Entinostat weekly |
|---|
| All Participants | 1200 | 5 |
Trials
1 trial available for entinostat and Weight Loss